ENSG00000291006 and ovarian carcinoma: After treatment of ovarian cancer cells with cisplatin and niraparib, respectively, it was found that the survival of ovarian cancer cells with LOC730101 overexpression was significantly lower than that of the control group (Fig. 3B); the number of colonies of ovarian cancer cells with LOC730101 overexpression was significantly reduced compared with that of the control group (Fig. 3E, F); the apoptosis rate of ovarian cancer cells with LOC730101 overexpression was significantly more than that of the control group (Fig. 3C, D).